CRANEWARE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,460 GBX | +2.50% |
|
+10.31% | +40.57% |
| Apr. 16 | Craneware extends share buyback scheme again by three months | AN |
| Apr. 16 | Craneware plc's Equity Buyback Plan Extended till July 17, 2024. | CI |
Financials (USD)
| Sales 2024 * | 185M | Sales 2025 * | 198M | Capitalization | 1.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 11M | Net income 2025 * | 15M | EV / Sales 2024 * | 5.91 x |
| Net cash position 2024 * | 3.03M | Net cash position 2025 * | 12.6M | EV / Sales 2025 * | 5.45 x |
| P/E ratio 2024 * |
115
x | P/E ratio 2025 * |
86.2
x | Employees | 734 |
| Yield 2024 * |
1.16% | Yield 2025 * |
1.23% | Free-Float | 79.08% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +2.50% | ||
| 1 week | +10.31% | ||
| 1 month | +15.49% | ||
| 3 months | +17.14% | ||
| 6 months | +50.46% | ||
| Current year | +40.57% |
1 week
2 215.00
2 463.40
1 month
2 140.002 463.40
Current year
1 700.002 463.40
1 year
1 290.002 463.40
3 years
1 060.002 700.00
5 years
1 060.003 175.00
10 years
473.003 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Keith Neilson
FOU | Founder | 55 | 99-04-30 |
Craig Preston
DFI | Director of Finance/CFO | 53 | 08-09-14 |
Abhilesh Gandhi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russ Rudish
BRD | Director/Board Member | 72 | 14-08-27 |
Keith Neilson
FOU | Founder | 55 | 99-04-30 |
Colleen M. Blye
BRD | Director/Board Member | 64 | 13-11-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 2,460 | +2.50% | 228,925 |
| 24-05-30 | 2,400 | +4.80% | 49,672 |
| 24-05-29 | 2,290 | -.--% | 58,930 |
| 24-05-28 | 2,290 | +2.69% | 80,953 |
| 24-05-24 | 2,230 | -0.89% | 45,238 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotes
Craneware plc is a United Kingdom company that is engaged in the development, licensing and ongoing support of computer software for the United States healthcare industry. The Company is engaged in automated value cycle solutions, including 340B management, collaborates with United States healthcare providers to plan, execute, and monitor operational and financial performance, so they can deliver quality care to their communities. The Company combines revenue integrity, cost management, 340B performance, and decision enablement into a single, software-as-a-service (SaaS)-based platform. Its solutions include Trisus Pricing Transparency, Trisus Pricing Analyzer, Trisus Chargemaster, Insight Medical Necessity, Trisus Claims Informatics, Trisus Supply, Appeals Services, Trisus Supplies Assistant, Trisus Medication Analytic Solutions, Sentinel, Sentrex, Referral Verification System, Trisus Medication Formulary, Trisus Medication Financial Management, InSight Audit and others.
Sector
Software
Calendar
2024-06-23
- HFMA Conference
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
31.3
USD
Average target price
33.97
USD
Spread / Average Target
+8.53%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.57% | 1.09B | |
| +8.91% | 85.92B | |
| +5.14% | 77.93B | |
| -16.20% | 52.89B | |
| +26.18% | 48.28B | |
| +28.93% | 45.38B | |
| -34.05% | 40.83B | |
| +66.72% | 38.78B | |
| -0.36% | 27.48B | |
| -26.47% | 21.52B |
- Stock Market
- Equities
- CRW Stock
